Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Clinical evidence

FORTIFI-HN01

59 evidence topics · 15 sources

Objective
Location and study date
Study dates and sites in the ClinicalTrials.gov record
Study characteristicQuoted record
Study start (actual)“2025-01-28”
Primary completion (estimated)“2028-04”
Study completion (estimated)“2029-07”
Sites“This study has 231 locations”
Study design
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“Disease suitable for local therapy administered with curative intent.” (opens the source at this quote in a new tab)

“Prior treatment with anti-TGFβ therapy.” (opens the source at this quote in a new tab)

“Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).” (opens the source at this quote in a new tab)

“Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.” (opens the source at this quote in a new tab)

“Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.” (opens the source at this quote in a new tab)

“Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.” (opens the source at this quote in a new tab)

“Life expectancy less than 3 months.” (opens the source at this quote in a new tab)

“Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.” (opens the source at this quote in a new tab)

“Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.” (opens the source at this quote in a new tab)

“Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.” (opens the source at this quote in a new tab)

“Active autoimmune disease requiring systemic treatment in the past 2 years.” (opens the source at this quote in a new tab)

“Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.” (opens the source at this quote in a new tab)

“Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.” (opens the source at this quote in a new tab)

“Known history of human immunodeficiency virus (HIV).” (opens the source at this quote in a new tab)

“Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.” (opens the source at this quote in a new tab)

“Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.” (opens the source at this quote in a new tab)

“Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.” (opens the source at this quote in a new tab)

“Use of a live or live attenuated vaccine within 4 weeks prior to Screening.” (opens the source at this quote in a new tab)

“Other Inclusion/Exclusion criteria may apply as defined in the protocol.” (opens the source at this quote in a new tab)

HPV assay developer named in the EU trial record
Third partyQuoted record
Organization“Qiagen Manchester Limited”
Duty delegated by the sponsor“Development of HPV DNA Assay”
Treatment
Study outcomes
Rationale for using RECIST v1.1 objective response rate and overall survival as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

FORTIFI-HN01 has reported no efficacy, safety, or baseline results; the phase 3 dose selection rests on company statements that it was informed by the open-label phase 1/1b data sets and by data from the phase 2 treatment arms. Accelerated approval would rest on an interim ORR analysis, with clinical benefit verified by OS in the same trial, the design FDA draft guidance calls the “one-trial” approach; FDA draft guidance states that preserving trial integrity is critical to that approach, and Bicara states that “interim and preliminary data may not be predictive of final results” and that confirmatory studies may not show clinical benefit. The control arm is placebo plus pembrolizumab 200 mg every 3 weeks, and participants treated at 1500 mg weekly in phase 2 contribute to the primary analyses while those treated at 750 mg weekly do not.